SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Antibe Therapeutics Inc. (ATBPF) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 26/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ATBPF
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.37
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$-1.02 |
$0.00 |
$-2.68M |
- |
| 2015 |
$-1.19 |
$19.96K |
$-4.4M |
-22052.4% |
| 2016 |
$-0.42 |
$4.44M |
$-3.37M |
-75.8% |
| 2017 |
$-0.60 |
$9.05M |
$-5.75M |
-63.5% |
| 2018 |
$-0.49 |
$8.51M |
$-7.43M |
-87.3% |
| 2019 |
$-0.60 |
$9.54M |
$-12.82M |
-134.4% |
| 2020 |
$-0.71 |
$9.67M |
$-19.34M |
-200.1% |
| 2021 |
$-0.70 |
$9.71M |
$-26.3M |
-270.8% |
| 2022 |
$-0.49 |
$0.00 |
$-25.06M |
- |
| 2023 |
$-0.37 |
$0.00 |
$-19.48M |
- |
